Prof Ding Peirong is a professor and chief surgeon, and currently serves as the Director of the Department of Colorectal Surgery at Sun Yat-Sen University Cancer Center, China. His clinical research focuses on the management of hereditary colorectal cancer and the optimization of neoadjuvant strategies for locally advanced rectal cancer. He leads several randomized clinical trials, including studies on the use of PD‑1 antibodies for adenoma and secondary malignancy prevention, as well as adjuvant immunotherapy with PD‑1 antibodies for stage III MSI‑H colorectal cancer.
His laboratory research centers on elucidating the mechanisms underlying hereditary colorectal cancer syndromes and early‑onset colorectal cancer, as well as understanding the impact of the tumor microenvironment on immunotherapy responses in colorectal cancer.
As corresponding or first author, he has published more than 100 papers in leading journals such as Lancet Oncology, Cancer Cell, Journal of Clinical Oncology, Cell Research, Nature Communications, JNCI, JNCCN, Annals of Surgery, EBioMedicine, JITC, and European Journal of Human Genetics, among others.
He has previously served as President of the Society of Hereditary Cancer of the Chinese Anti‑Cancer Association, and as Vice President of the Committee of Youth Experts of the Chinese Society of Clinical Oncology.
